Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

Antonio Gasbarrini, Rosa Anna Bruno, Salvatore Petta, Giuseppe Cabibbo, Marco Enea, Fabio Salvatore Macaluso, Antonella Plaia, Raffaele Bruno, Savino Bruno, Antonio Craxì, Calogero Cammà

Risultato della ricerca: Contributo in rivistaArticolo in rivista

18 Citazioni (Scopus)

Abstract

We assessed the cost-effectiveness of boceprevir-based triple therapy compared to peginterferon alpha and ribavirin dual therapy in untreated patients with genotype 1 chronic hepatitis C; patients were discriminated according to the combination of baseline plus on-treatment predictors of boceprevir-based triple therapy.
Lingua originaleEnglish
pagine (da-a)936-942
Numero di pagine7
RivistaDIGESTIVE AND LIVER DISEASE
Volume46
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • Boceprevir
  • Cost-effectiveness
  • Peg-interferon

Fingerprint Entra nei temi di ricerca di 'Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C'. Insieme formano una fingerprint unica.

Cita questo